Boston – February 2, 2017 – Cooley advised Tarveda Therapeutics on its $30 million Series D financing round. New investor Versant Ventures led the round, which also included existing investors New Enterprise Associates, Novo A/S, NanoDimension and Flagship Pioneering.
Tarveda plans to use the funding, in addition to the $38 million raised in its Series C financing in 2016, to advance its novel Pentarin platform.
Tarveda discovers and develops Pentarins, a new class of potent and selective miniaturized drug conjugates with enhanced targeting capabilities for the treatment of solid cancer tumors. Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniaturized drug conjugate that targets the somatostatin receptor 2 for treatment of patients with neuroendocrine and small cell lung cancers.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.